Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS

Laboratory Investigation

Volumn 87, Issue 11, 2007, Pages 1113-1124

  Wallentine, Jeremy C ^a   Kim, Ki Kwon ^a   Seiler III, Charles E ^a   Vaughn, Cecily P ^b   Crockett, David K ^b   Tripp, Sheryl R ^b   Elenitoba Johnson, Kojo S J ^a,b   Lim, Megan S ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bioinformatics analysis; Biomarker discovery; Hodgkin lymphoma; Shotgun proteomics; Tandem mass spectrometry

Indexed keywords

AXIN; B RAF KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FUNCTIONAL GROUP; MUCIN 2; PROTEIN KINASE PIM 1; PROTEOME; TENASCIN;

ANALYTICAL ERROR; ARTICLE; BIOINFORMATICS; CARCINOGENICITY; CELL COMPARTMENTALIZATION; CELL FRACTIONATION; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSOL; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL LINE; PEPTIDE ANALYSIS; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN SECRETION; PROTEOMICS; REED STERNBERG CELL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; VALIDATION PROCESS; WESTERN BLOTTING;

CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEOME; REED-STERNBERG CELLS; SUBCELLULAR FRACTIONS; TANDEM MASS SPECTROMETRY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 35348991105     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700672     Document Type: Article

References (45)

1. Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol 2000;12:383-394.
2. Lee IS, Kim SH, Song HG, et al. The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma. Int J Hematol 2003;77:330-335.
3. Jacobs P. Hodgkin's disease and the malignant lymphomas. Dis Mon 1993;39:213-297.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
5. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994;12:580-586.
6. Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395-1404.
7. Clodi K, Asgari Z, Younes M, et al. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 2002;94:1-5.
8. Fischer M, Bijman M, Molin D, et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 2003;17:2513-2516.
9. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003;123:850-857.
10. Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:1664-1673.
11. Newcom SR, Ansari AA, Gu L. Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell. Blood 1992;79:191-197.
12. Newcom SR, Kadin ME, Ansari AA, et al. L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest 1988;82:1915-1921.
13. Blagosklonny MV, Neckers LM. The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line. Eur Cytokine Netw 1995;6:21-27.
14. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006;5:787-796.
15. Salles G, Bienvenu J, Bastion Y, et al. Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol 1996;93:352-359.
16. Lim MS, Elenitoba-Johnson KS. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol Cell Proteomics 2006;5:1787-1798.
17. Jiang XS, Zhou H, Zhang L, et al. A high-throughput approach for subcellular proteome: identification of rat liver proteins using subcellular fractionation coupled with two-dimensional liquid chromatography tandem mass spectrometry and bioinformatic analysis. Mol Cell Proteomics 2004;3:441-455.
18. Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab Invest 2004;84:1227-1244.
19. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-240.
20. Lin YW, Lin CY, Lai HC, et al. Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl 1):139-146.
21. Li J, Zhao J, Yu X, et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005;11:8312-8320.
22. Fujii K, Kondo T, Yokoo H, et al. Protein expression pattern distinguishes different lymphoid neoplasms. Proteomics 2005;5:4274-4286.
23. Wu SL, Hancock WS, Goodrich GG, et al. An approach to the proteomic analysis of a breast cancer cell line (SKBR-3). Proteomics 2003;3:1037-1046.
24. Keller A, Nesvizhskii AI, Kolker E, et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-5392.
25. Nesvizhskii AI, Keller A, Kolker E, et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-4658.
26. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4:R28.
27. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001. Lyon: IARC Press.
28. Harper JA, Yuan JS, Tan JB, et al. Notch signaling in development and disease. Clin Genet 2003;64:461-472.
29. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48-54.
30. Pahlman S, Stockhausen MT, Fredlund E, et al. Notch signaling in neuroblastoma. Semin Cancer Biol 2004;14:365-373.
31. Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398-3403.
32. Knoops L, Renauld JC. IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 2004;22:207-215.
33. Lee JW, Yoo NJ, Soung YH, et al. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer 2003;89:1958-1960.
34. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-532.
35. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-193.
36. Montesinos-Rongen M, Van Roost D, Schaller C, et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103:1869-1875.
37. Rainio EM, Ahlfors H, Carter KL, et al. Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. Virology 2005;333:201-206.
38. Bieche I, Onody P, Tozlu S, et al. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-765.
39. Quinn CM, Ostrowski JL, Lane SA, et al. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994;25:247-252.
40. Walters DK, French JD, Arendt BK, et al. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex. Oncogene 2003;22:3598-3607.
41. Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005;58:225-236.
42. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-499.
43. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia 1995;51:853-862.
44. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997;47:813-830.
45. Elhabazi A, Marie-Cardine A, Chabbert-de Ponnat I, et al. Structure and function of the immune semaphorin CD100/SEMA4D. Crit Rev Immunol 2003;23:65-81.